North America is expected to form the largest regional segment in the global tumor ablation market in 2016, followed by Europe. The Asia-Pacific market is expected to form the fastest-growing region, with a double-digit CAGR during 2016-2021. A number of factors including increasing prevalence of cancer coupled with rising geriatric population, increasing medical tourism due to lower treatment costs, growing market penetration of major players, and evolving regulatory scenario are stimulating the growth of the tumor ablation market in the Asia-Pacific region.

Download PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=142550

Emerging markets (such as China and India) are offering high growth opportunities for market players operating in the tumor ablation industry. Increasing prevalence of cancer along with rising elderly population and growing medical tourism across major Asian countries are driving the demand for tumor ablation products in emerging nations. In order to leverage growth opportunities in these emerging nations, leading market players are expanding their presence in these countries.

Speak to analyst @ http://www.marketsandmarkets.com/speaktoanalyst.asp?id=142550258

As of 2015, Angiodynamics, Inc. (U.S.), Boston Scientific Corporation (U.S.), Galil Medical, Inc. (U.S.), EDAP TMS S.A. (France), Healthtronics, Inc. (U.S.), Medtronic, Plc (U.S.), Mermaid Medical, Inc. (Denmark), Mesonix, Inc. (U.S.), Neuwave Medical, Inc. (U.S.), and Sonacare Medical, LLC (U.S.) are key players operating in the global tumor ablation market.